Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Integra Lifesciences Holdings (IART) over the last 17 years, with Q3 2025 value amounting to $15.2 million.

  • Integra Lifesciences Holdings' Capital Expenditures fell 4887.67% to $15.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $93.8 million, marking a year-over-year decrease of 556.7%. This contributed to the annual value of $104.4 million for FY2024, which is 5616.24% up from last year.
  • Per Integra Lifesciences Holdings' latest filing, its Capital Expenditures stood at $15.2 million for Q3 2025, which was down 4887.67% from $20.1 million recorded in Q2 2025.
  • In the past 5 years, Integra Lifesciences Holdings' Capital Expenditures ranged from a high of $29.7 million in Q2 2024 and a low of $6.6 million during Q2 2021
  • Moreover, its 5-year median value for Capital Expenditures was $15.2 million (2025), whereas its average is $17.2 million.
  • Examining YoY changes over the last 5 years, Integra Lifesciences Holdings' Capital Expenditures showed a top increase of 22546.58% in 2021 and a maximum decrease of 5959.2% in 2021.
  • Integra Lifesciences Holdings' Capital Expenditures (Quarter) stood at $27.4 million in 2021, then plummeted by 47.29% to $14.5 million in 2022, then surged by 69.72% to $24.5 million in 2023, then grew by 20.64% to $29.6 million in 2024, then tumbled by 48.8% to $15.2 million in 2025.
  • Its Capital Expenditures was $15.2 million in Q3 2025, compared to $20.1 million in Q2 2025 and $28.9 million in Q1 2025.